文献速递神经免疫认知障碍与痴呆

用影像区分多发性硬化与AQP4-视神经脊髓炎谱系疾病及MOG抗体病

Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging.
PubMed 文献 · Neurology · 2022-10-03

研究前瞻性纳入91例成人非急性期患者(31例RRMS、30例AQP4-NMOSD、30例MOGAD)及34名健康对照,行脑、脊髓、视神经MRI与OCT检查。中央静脉征比例、皮质病灶及视神经磁化传递率联合可高准确度区分RRMS与AQP4-NMOSD;白质病灶数等可区分RRMS与MOGAD。

要点

  • 中央静脉征比例区分RRMS与AQP4-NMOSD准确度91%,敏感度93%、特异度88%。
  • 白质病灶数区分RRMS与MOGAD准确度94%,敏感度93%、特异度94%。
  • 联合中央静脉征、皮质病灶及视神经MTR区分RRMS与AQP4-NMOSD准确度达95%。

核心结论

  • 皮质病灶、中央静脉征和视神经标志物可高准确度区分RRMS与AQP4-NMOSD及MOGAD,在非急性期及血清学结果不明确或不可及时可能有助于临床实践。
  • 本研究提供II级证据:所选常规与先进脑、脊髓、视神经MRI及OCT标志物可区分成人RRMS与AQP4-NMOSD及MOGAD。

研究设计与样本

  • 前瞻性招募成人非急性期RRMS、AQP4-NMOSD、MOGAD患者及健康对照,2014年至2019年在伦敦国家神经病学与神经外科医院及利物浦沃尔顿中心进行。
  • 共纳入91例连续患者(31例RRMS、30例AQP4-NMOSD、30例MOGAD)和34名健康对照。
  • 所有受试者接受常规与先进脑、脊髓、视神经MRI及光学相干断层扫描(OCT)。

主要发现

  • 区分RRMS与AQP4-NMOSD最准确的指标为中央静脉征病灶比例(84% vs 33%,准确度/特异度/敏感度91/88/93%,p < 0.001)。
  • 皮质病灶区分RRMS与AQP4-NMOSD:中位数2(范围1-14) vs 1(0-1),准确度/特异度/敏感度84/90/77%,p = 0.002。
  • 白质病灶区分RRMS与AQP4-NMOSD:均值39.07(±25.8) vs 9.5(±14),准确度/特异度/敏感度78/84/73%,p = 0.001。
  • 区分RRMS与MOGAD最准确的指标为白质病灶(39.07 [±25.8] vs 1 [±2.3],准确度/特异度/敏感度94/94/93%,p = 0.006)。
  • 视网膜神经纤维层厚度区分RRMS与MOGAD:均值87.54(±13.83) vs 75.54(±20.33),准确度/特异度/敏感度80/79/81%,p = 0.009。

关键数值与推荐

  • 联合较高中央静脉征比例、皮质病灶及视神经磁化传递率区分RRMS与AQP4-NMOSD:准确度/特异度/敏感度95/92/97%,p < 0.001。
  • 较高皮质病灶数联合较高视网膜神经纤维层厚度区分RRMS与MOGAD:准确度/特异度/敏感度84/92/77%,p < 0.001。
  • 皮质病灶区分RRMS与MOGAD:中位数2(1-14) vs 1(0-1),准确度/特异度/敏感度84/97/71%,p = 0.004。

临床怎么用

  • 作者认为,皮质病灶、中央静脉征和视神经标志物在区分RRMS与AQP4-NMOSD及MOGAD方面具有高准确度,在非急性期及血清学结果不明确或不可及时可能有助于临床实践。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Relapsing-remitting multiple sclerosis (RRMS), aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) may have overlapping clinical features. There is an unmet need for imaging markers that differentiate between them when serologic testing is unavailable or ambiguous. We assessed whether imaging characteristics typical of MS discriminate RRMS from AQP4-NMOSD and MOGAD, alone and in combination. METHODS: Adult, nonacute patients with RRMS, APQ4-NMOSD, and MOGAD and healthy controls were prospectively recruited at the National Hospital for Neurology and Neurosurgery (London, United Kingdom) and the Walton Centre (Liverpool, United Kingdom) between 2014 and 2019. They underwent conventional and advanced brain, cord, and optic nerve MRI and optical coherence tomography (OCT). RESULTS: A total of 91 consecutive patients (31 RRMS, 30 APQ4-NMOSD, and 30 MOGAD) and 34 healthy controls were recruited. The most accurate measures differentiating RRMS from AQP4-NMOSD were the proportion of lesions with the central vein sign (CVS) (84% vs 33%, accuracy/specificity/sensitivity: 91/88/93%, p < 0.001), followed by cortical lesions (median: 2 [range: 1-14] vs 1 [0-1], accuracy/specificity/sensitivity: 84/90/77%, p = 0.002) and white matter lesions (mean: 39.07 [±25.8] vs 9.5 [±14], accuracy/specificity/sensitivity: 78/84/73%, p = 0.001). The combination of higher proportion of CVS, cortical lesions, and optic nerve magnetization transfer ratio reached the highest accuracy in distinguishing RRMS from AQP4-NMOSD (accuracy/specificity/sensitivity: 95/92/97%, p < 0.001). The most accurate measures favoring RRMS over MOGAD were white matter lesions (39.07 [±25.8] vs 1 [±2.3], accuracy/specificity/sensitivity: 94/94/93%, p = 0.006), followed by cortical lesions (2 [1-14] vs 1 [0-1], accuracy/specificity/sensitivity: 84/97/71%, p = 0.004), and retinal nerve fiber layer thickness (RNFL) (mean: 87.54 [±13.83] vs 75.54 [±20.33], accuracy/specificity/sensitivity: 80/79/81%, p = 0.009). Higher cortical lesion number combined with higher RNFL thickness best differentiated RRMS from MOGAD (accuracy/specificity/sensitivity: 84/92/77%, p < 0.001). DISCUSSION: Cortical lesions, CVS, and optic nerve markers achieve a high accuracy in distinguishing RRMS from APQ4-NMOSD and MOGAD. This information may be useful in clinical practice, especially outside the acute phase and when serologic testing is ambiguous or not promptly available. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that selected conventional and advanced brain, cord, and optic nerve MRI and OCT markers distinguish adult patients with RRMS from AQP4-NMOSD and MOGAD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Cortese R, Prados Carrasco F, Tur C, et al. Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging. Neurology. 2022. PMID: 36192175. doi:10.1212/WNL.0000000000201465

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。